Delving into the Latest Updates on Henan Normal University with Synapse

Overview

Tags

Nervous System Diseases

Immune System Diseases

Respiratory Diseases

Small molecule drug

Recombinant protein

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Infectious Diseases	1
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	4
Recombinant protein	2

Top 5 Target	Count

BDNF x M1 receptor	1
SEMA3A(semaphorin 3A)	1
RT(Viral reverse transcriptase)	1
EGFR T790M(Epidermal Growth Factor Receptor T790M)	1
ISM1(isthmin 1)	1

主要目的：评价甲磺酸哆希替尼片（90-1408）治疗EGFR 突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者的安全性和耐受性。次要目的：评价90-1408 治疗EGFR 突变阳性的局部晚期或转移性NSCLC 患者单次给药/多次给药的药代动力学（PK）特征；确定90-1408 治疗EGFR 突变阳性的局部晚期或转移性NSCLC 患者的剂量限制性毒性（DLT）和最大耐受剂量（MTD）；评价90-1408 治疗EGFR 突变阳性的局部晚期或转移性NSCLC 患者的初步有效性；评价90-1408 治疗T790M 突变阳性的局部晚期或转移性NSCLC 患者的初步有效性；评价90-1408 治疗T790M 突变阳性的局部晚期或转移性NSCLC 患者的安全性；探索90-1408 血浆、尿液中的药物代谢谱。

[Translation]

Main purpose: To evaluate the safety and tolerability of doxitinib mesylate tablets (90-1408) in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutation-positive. Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of single/multiple administration of 90-1408 in the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations; To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of 90-1408 in the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations; To evaluate the preliminary efficacy of 90-1408 in the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations; To evaluate the preliminary efficacy of 90-1408 in the treatment of patients with locally advanced or metastatic NSCLC with T790M mutations; To evaluate the safety of 90-1408 in the treatment of patients with locally advanced or metastatic NSCLC with T790M mutations; To explore the drug metabolism profile of 90-1408 in plasma and urine.

Start Date01 Jun 2022

Sponsor / Collaborator

Henan Meitaibao Biopharmaceutical Co., Ltd.

[+2]

100 Clinical Results associated with Henan Normal University

Login to view more data

0 Patents (Medical) associated with Henan Normal University

Login to view more data

20,971

Literatures (Medical) associated with Henan Normal University

01 Apr 2025·Journal of Environmental Sciences

Mobilization of heavy metals from floodplain sediments of the Yellow River during redox fluctuations

Article

Author: Meng, Ying ; Xie, Fuyu ; Li, Xiaoqing ; Yang, Qingxiang ; Luan, Fubo

The floodplain of the Yellow River is a typical area characterized by redox fluctuations and heavy metal pollution. However, the mobilization behavior of heavy metals in floodplain sediments during redox fluctuations remains poorly understood. In this study, reductive mobilization of Fe and Mn was observed under reducing environments through reduction and dissolution, leading to the subsequent release of adsorbed As. In contrast, the mobilization of U occurred under oxic conditions, as the oxidative state of U(VI) has higher solubility. Furthermore, insignificant effects on the mobilization of Cd, Cu, Pb, and Hg were noticed during redox fluctuations, indicating higher stability of these heavy metals. Additionally, we demonstrated that carbon sources can play a key role in the mobilization of heavy metals in floodplain sediments, amplifying the reductive mobilization of Fe, Mn, As and the oxidative mobilization of U. Our findings contribute to the understanding of the biogeochemical cycling of heavy metal in floodplain sediments of the Yellow River and the factors that control this cycling.

01 Jan 2025·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

An ultrasensitive and specific fluorescence split-aptasensor for VEGF165 detection based on nicking enzyme-assisted 3D DNA walker coupling with CRISPR-Cas12a

Article

Author: Wang, Gongke ; Xiong, Bowen ; Zhang, Yuting ; Yan, Changling ; Li, Xiang

The overexpression of vascular endothelial growth factor 165 (VEGF₁₆₅) in cancer cells plays a pivotal role in promoting tumor metastasis by facilitating their excessively rapid proliferation and division. Hence, the development of analytical methods possessing high sensitivity and resistance to interference is imperative for the detection of VEGF₁₆₅. Various types of aptasensors have been devised for VEGF₁₆₅ detection; however, the performance of these biosensors can be influenced by non-target signals caused by conformational changes in unbound aptamers. The paper shows the creation of a precise and sensitive fluorescence biosensor designed to detect VEGF₁₆₅ by using a VEGF₁₆₅-specific split aptamer. Additionally, this biosensor employs nicking enzyme-assisted DNA walker coupling with CRISPR-Cas12a to achieve dual-signal amplification. The VEGF₁₆₅ calibration curve shows a detection limit of 268 fM and has a broad linear range from 5 to 4000 nM. The fluorometric biosensor was utilized to detect VEGF₁₆₅ in human serum and cellular homogenate samples, yielding good outcomes. The innovative design serves as proof of concept and demonstrates significant potential in detecting various targets.

01 Jan 2025·Methods in Molecular Biology

Identifying an Abnormal Phosphorylated Adaptor by Viral Kinase Using Mass Spectrometry

Article

Author: Zheng, Chunfu ; Su, Chenhe ; Su, Chenhao

Mass spectrometers are widely used to identify protein phosphorylation sites. The process usually involves selective isolation of phosphoproteins and subsequent fragmentation to identify both the peptide sequence and phosphorylation site. Immunoprecipitation could capture and purify the protein of interest, greatly reducing sample complexity before submitting it for mass spectrometry analysis. This chapter describes a method to identify an abnormal phosphorylated site of the adaptor protein by a viral kinase through immunoprecipitation followed by LC-MS/MS.

100 Deals associated with Henan Normal University

Login to view more data

100 Translational Medicine associated with Henan Normal University

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

1

Preclinical

Phase 1 Clinical

1

Phase 2 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Doxitinib mesylate ( EGFR T790M )	Secondary malignant neoplasm of lung More	Phase 2 Clinical
CL-197 ( RT )	HIV Infections More	Phase 1
S-3a ( BDNF x M1 receptor )	Depressive Disorder More	Preclinical
FSD-C10 ( ROCK )	Alzheimer Disease More	Discovery
CN116024221 ( ISM1 )	Liver Diseases More	Discovery